Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

Géraud, A; Xu, H P; Beuzeboc, P; Kirova, Y M

Géraud, A; Xu, H P; Beuzeboc, P; Kirova, Y M.

Affiliation

Géraud A; Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Xu HP; Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Beuzeboc P; Department of medical oncology, 26, rue d'Ulm, 75005 Paris, France.
Kirova YM; Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.

Cancer Radiother ; 20(4): 312-3, 2016 Jun.

Article in En | MEDLINE | ID: mdl-27342941

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents/therapeutic use; Bone Neoplasms/therapy; Breast Neoplasms/pathology; Chemoradiotherapy; Maytansine/analogs & derivatives; Ado-Trastuzumab Emtansine; Adult; Bone Neoplasms/secondary; Breast Neoplasms/metabolism; Female; Humans; Maytansine/therapeutic use; Middle Aged; Radiation Dose Hypofractionation; Receptor, ErbB-2/metabolism; Trastuzumab

Key words

Concurrent treatment; Metastatic breast cancer; Radiotherapy; TDM1; Toxicity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Breast Neoplasms / Antibodies, Monoclonal, Humanized / Chemoradiotherapy / Maytansine / Antineoplastic Agents Limits: Adult / Female / Humans / Middle aged Language: En Journal: Cancer Radiother Journal subject: NEOPLASIAS / RADIOTERAPIA Year: 2016 Document type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google